Company intelligence / Profile preview

Ecotone

Brooklyn, New York, United States

Ownership: Private
Development stage: Other

Overview

Ecotone is a biotech company developing frontier AI models to read the human genome as a first language, aiming to accelerate the discovery and development of gene therapies for rare genetic diseases. Their platform, dnaSORA, dramatically improves the ability to identify disease-causing genes using genomic data from as few as several dozen patients, reducing drug development costs by up to 70% compared to current industry standards[3][7]. The technology can isolate disease-causing genomic regions at 0.3 megabase resolution, a significant leap over current pharmaceutical industry methods[3][7].

Therapeutic areas: Rare Diseases
Modalities: CRISPR-based therapyGene therapy
Industry: Biotech

Beyond the preview

Go deeper on Ecotone.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ecotone.

Explore the full profile